Direct status answer
MOTS-c has no FDA-approved finished-drug label
FDA drug approval and compounding-policy review are different regulatory pathways. An FDA-approved drug has an approved application and prescribing information for specific uses, formulations, and conditions. MOTS-c does not have that kind of FDA-approved prescribing label. A compounded MOTS-c prescription, when discussed in clinician-reviewed care, must not be described as an FDA-approved finished drug or as equivalent to a product studied under a clinical-trial protocol.
- “FDA reviewed,” “on an FDA agenda,” “nominated for the 503A bulks list,” and “FDA approved” do not mean the same thing.
- FDA does not review compounded drugs for safety, effectiveness, or quality before marketing in the same way it reviews approved drug products.
- An endogenous peptide found in the body is not automatically an approved, safe, or legally marketable treatment product.
July 2026 PCAC context
The July review was a compounding-policy question—not a treatment approval
The Federal Register notice and FDA meeting materials placed MOTS-c free base and acetate in a Pharmacy Compounding Advisory Committee review concerning bulk drug substances nominated for the section 503A bulks list. PCAC provides advisory input to FDA. The agenda, briefing materials, public discussion, and any committee recommendation do not by themselves approve MOTS-c, create a drug label, prove effectiveness, or settle every federal and state compounding question. After the meeting dates, patients should still look for a separate, current FDA record before accepting claims about a final agency determination.
- The official notice identified the July 23–24, 2026 meeting and docket FDA-2025-N-6895; the legal notice is not a consumer authorization to purchase MOTS-c.
- A bulks-list decision concerns conditions for certain compounding activity. It is narrower than a clinician’s diagnosis, eligibility, informed-consent, pharmacy, and monitoring decisions.
- Do not infer a final FDA outcome from an agenda page, meeting video, committee vote, clinic email, influencer post, or seller headline alone.
Human evidence
A recruiting Phase 2 study does not make MOTS-c approved or proven
ClinicalTrials.gov lists NCT07505745 as a recruiting, randomized Phase 2 study of an investigational MOTS-c product in an estimated 120 adults with prediabetes and overweight or obesity. The registry says no results are posted. Foundational MOTS-c research includes cell and animal work, reviews, and studies measuring naturally circulating mitochondrial-derived peptides in people. Those sources can support research questions, but they do not establish an approved indication, consumer dosing plan, finished-product equivalence, long-term safety, or reliable outcome claims for compounded or online products.
- Clinical-trial registration means a question is being studied under a protocol; it is not FDA approval and is not evidence that a retail product matches the study product.
- Cell, animal, mechanism, biomarker, and endogenous-peptide studies should not be converted into guaranteed weight-loss, glucose, exercise, osteoporosis, or longevity outcomes.
- Until controlled human results and product-specific regulatory records are available, clinicians should describe the evidence and uncertainty separately.
Access and legality questions
“Is MOTS-c legal?” is not answered by one marketing phrase
MOTS-c access can involve federal compounding conditions, state pharmacy and prescribing rules, the exact formulation, the prescriber, the pharmacy, patient-specific clinical need, and future FDA action. A page cannot determine whether a particular product or transaction is lawful. Patients should ask the responsible clinician and dispensing pharmacy to identify the product pathway in writing and should verify current FDA and state-board information rather than relying on “legal peptide,” “not banned,” or “research only” language.
- A legitimate clinical pathway should identify the licensed prescriber, dispensing pharmacy, active ingredient, formulation, route, lot, storage and beyond-use information, compounded status, and follow-up contact.
- A certificate of analysis does not replace an approved application, lawful prescription pathway, pharmacy accountability, sterility controls, or patient-specific monitoring.
- No-prescription checkout, bulk powder, “research use only” vials promoted for self-treatment, hidden pharmacy identity, copied dosing charts, or crypto-only payment are major red flags.
Patient decision boundary
Regulatory interest does not answer whether MOTS-c is appropriate for you
Even if a future FDA or compounding-policy status changes, an individual still needs diagnosis-first care, alternatives, medication review, risk screening, product-specific consent, and follow-up. MOTS-c marketing often targets weight, glucose, exercise, osteoporosis, energy, or healthy-aging goals, but those goals can also point to established medical evaluations and approved treatments. Do not delay evidence-based care or change diabetes, cardiovascular, bone-health, cancer, pregnancy, or other treatment based on a peptide-status headline.
- Bring current medicines, supplements, other peptides, allergies, pregnancy plans, cancer history, kidney or liver disease, cardiovascular history, glucose data, and sports-testing requirements to the review.
- Do not copy a trial regimen, seller cycle, injection map, or social-media stack, and do not stop an approved medicine to make room for MOTS-c.
- Seek urgent care for severe allergic symptoms, breathing difficulty, fainting, confusion, chest pain, persistent vomiting or dehydration, severe low-blood-sugar symptoms, or a rapidly worsening injection-site reaction.